Compounded Peptides ·
Several US states have tightened regulations on compounding pharmacies preparing GLP-1 peptides. State boards of pharmacy in Mississippi, Louisiana, and Tennessee issued guidance through 2025 limiting the circumstances under which 503A pharmacies can prepare compounded semaglutide and tirzepatide. California's state board has required additional licensure disclosures for out-of-state compounders shipping into California. These state-level actions operate alongside federal FDA enforcement and reflect the traditional state role in licensing pharmacies. The patchwork of state rules has made compliance more complex for multistate telehealth operators through early 2026.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.